After DEA’s of its draft temporary rule last week, the Drug Enforcement Administration (“DEA”) has officially published a temporary rule expanding COVID-19 related flexibilities for prescribing controlled substances via telehealth. The... Read More
Combatting opioid diversion remains a top priority for regulators and enforcement agencies. In that vein, there continues to be enhanced scrutiny on healthcare professionals over opioid prescriptions. As highlighted by recent Department of... Read More
On Friday, February 24, 2023, the Drug Enforcement Agency (“DEA”) issued long awaited proposed rules for prescribing controlled substances via telehealth after the conclusion of the COVID-19 Public Health Emergency (“PHE”). The Controlled... Read More
On January 30, 2023, the Biden Administration announced that the COVID-19 Public Health Emergency (“PHE”), which has been in effect since January 2020, is set to expire on May 11, 2023. Considering the impending end to the PHE, healthcare... Read More
A recent U.S. Supreme Court decision in the case of Ruan v. United States clarified the “intent element” in prosecutions of physicians for violations of the federal Controlled Substances Act (“CSA”) that are based on allegations... Read More
On June 29, 2022, the Department of Justice (“DOJ”) announced the formation of the New England Prescription Opioid (NEPO) Strike Force. This strike force will investigate and vigorously prosecute healthcare providers involved in healthcare fraud... Read More
Earlier this week, the U.S. Supreme Court ruled that to secure convictions under the federal Controlled Substances Act (“CSA”) for excessive prescribing of controlled substances, including opioids, prosecutors must prove beyond a reasonable... Read More
On November 10, 2021, the U.S. Department of Health and Human Services, Office of Inspector General (“OIG”), published an Advisory Opinion (AO# 21-15) regarding a proposal to employ a Certified Registered Nurse Anesthetist (“CRNA”), on a... Read More
The U.S. Attorney’s Office for the Eastern District of Pennsylvania recently announced several False Claims Act settlements and a new complaint against a Kansas chiropractor concerning allegations of improper billing for the use of certain P-Stim... Read More
At a court hearing on November 24, 2020, a bankruptcy judge approved a settlement entered in late October between Purdue Pharma L.P. (“Purdue”) and the Department of Justice (“DOJ”), under which Purdue Pharma L.P. plead guilty in New Jersey... Read More
